New Drug Approvals - Pt. XII - Dronedarone (Multaq)

Another drug reaching the market this year is Dronedarone (trade name Multaq), approved on July 1st. Dronedarone is a antiarrythmic agent indicated to reduce the risk of cardiovascular hospitalization in patients with a history of heart rhythm disorders. The drug is approved to be used in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat. Dronedarone is an antiarrythmic agent of unknown detailed mechanism of action (specifically it does not fit into one of the existing Vaughn Williams classification scheme), but is known to be a multi-channel blocker that affects calcium, potassium and sodium channels and also has anti-adrenergic receptor activity. Dronedarone (previously known by the research code SR33589) is a relatively large small molecule drug (Molecular Weight of 556.8 g.mol-1 for Dronedarone itself, and 593.2 g.mol-1 for the HCl salt), highly lipophilic and practically insoluble in water. Dronedarone has low systemic bioavailabity (~4%, increasing to ~15% if administrated with high fat meal, this low absolute oral bioavailability is due to extensive first-pass metabolism). Dronedarone has a volume of distribution of 1400L, and a high plasma protein binding of >98%. Dronedarone is extensively metabolized, mainly by CYP3A4, to the active N-debutyl metabolite and also to some inactive metabolites. The N-debutyl metabolite exhibits some pharmacologic activity but is much less potent than Dronedarone itself. Dronedarone is mostly excreted in the feces, mainly as metabolites. It has a plasma clearance of 130-150 L/hour and an elimination half-life of 13-19 hours. Recommended dosage is one tablet of 400 mg (equivalent to ca. 670 umol) twice a day, taken with morning and evening meals (see the higher bioavailability when taken with food discussed above). The full prescribing information can be found here.

Dronedarone has a boxed warning (colloquially known as 'black box').

The Dronedarone structure is N-{2-butyl-3-[4-(3-dibutylaminopropoxy)benzoyl]benzofuran-5-yl}methanesulfonamide. It contains an aryl sulfonamide and a tertiary amine. The amine is clearly basic in nature, but aryl sulphonamides are often weak acids, and are surprisingly common in drug structures. Dronedarone is a benzofuran derivative, chemically similar to Amiodarone, a widely used and early (discovered in 1961) class III antiarrhythmic agent, whose clinical use is often limited by a multitude of side effects.

Dronedarone canonical SMILES: O=S(=O)(Nc3cc1c(oc(c1C(=O)c2ccc(OCCCN(CCCC)CCCC)cc2)CCCC)cc3)C Dronedarone InChI: InChI=1/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18- 28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20 -10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3 Dronedarone InChIKey: ZQTNQVWKHCQYLQ-UHFFFAOYAL Dronedarone CAS registry: 141626-36-0 Dronedarone ChemDraw: Dronedarone.cdx

The license holder for Dronedarone is Sanofi-Aventis and the product website is www.multaq.com.

Comments

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains: 2,431,025 compounds (of which 2,409,270 have mol files) 3,106,257 compound records (non-unique compounds) 20,772,701 activities 1,644,390 assays 15,598 targets 89,892 documents Data can be downloaded from the ChEMBL FTP site: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and here for a reminder of SureChEMBL is and what it does. This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for local (behind the

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

The ChEMBL-og

Search This Blog